Novartis Spin-Off Sandoz Set to Launch Trading on Oct. 4
Shares expected to be offered on Six Swiss Exchange.
Novartis has officially confirmed it’s spin-off, Sandoz, with trading of new Sandoz Group AG shares and American Depositary Receipts (ADRs) to commence on Oct. 4. Expected to be listed and traded on the Six Swiss Exchange, Sandoz will be included in the Swiss Performance Index (SPI), Swiss Leader Index (SLI) and other relevant Swiss indices following completion of the Spin-off, as announced by the SIX Swiss Exchange.
According to a company press release, Sandoz has secured debt financing of $375 million through a group of banks which will also support the company with a credit facility of $1.25 billion.
Reference: Novartis confirms Sandoz Spin-off for October 4, 2023. Novartis. September 25, 2023. Accessed September 26, 2023. https://www.novartis.com/news/media-releases/novartis-confirms-sandoz-spin-october-4-2023
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
